Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|September 21, 2018
Ethical Considerations in Adaptive Design Clinical TrialsThomas Laage, John W Loewy, Sandeep Menon, et al.JAMA|April 7, 2005
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trialJames C Garbutt, Henry R Kranzler, Stephanie S O'Malley, et al.Plos One|June 24, 2022
A framework for assessing the impact of accelerated approvalA Lawrence Gould, Robert K Campbell, John W Loewy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignanciesChristine M Hartford, Apurva A Desai, Linda Janisch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapyGeorge D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.Pageof 1